QSAR Modeling for Relative Toxicity Prediction of (3-(2-chloroquinolin-3-yl)oxiran-2-yl)(phenyl) methanone Derivatives
Journal: Current Research in Pharmaceutical Sciences (Vol.7, No. 1)Publication Date: 2017-05-08
Authors : Amit Kumar Tiwari; Preveena Narasimhamurthy; Gopalpur Nagendrappa; Abhilash Thakur;
Page : 16-24
Keywords : QSAR analysis; Chloroquinoline; Rat; T.E.S.T.; Toxicity; medianlethaldose;
Abstract
2-Chloroquinoline-3-carbaldehyde and its substituted products are extremely versatile intermediates for synthesizing a variety of compounds containing quinoline moiety, which find many pharmaceutical and other applications. Quantitative structure-activity relationship (QSAR) plays an important role in toxicity prediction. The present study deals with acute toxicity predictions LD50 (medianlethal dose) values of (3-(2-chloroquinolin-3-yl)oxiran-2-yl)(phenyl) methanone and its derivatives in rat by oral exposure through QSAR modelling software package T.E.S.T. In the present study the toxicity (LD50) is evaluated using a variety of QSAR methodologies, such as hierarchical clustering, the Food and Drug Administration (FDA) MDL, nearest neighbor and a consensus model. For compounds No. 1 to 4, 7, 10 and 11 hierarchical clustering method does not provide the LD50 values; however, other methods have successfully provided the toxicity estimation for the same. The said software helps to predict the exact LD50 values when compared to experimental data reported in the range (>2000 to >5000 mg/kg). This is a preliminary observation from screening of LD50 values using the said software package. Further study may be relevant using other software to compare the predicted data.
Other Latest Articles
- Review on Pharmacology and Phytochemistry of Cyperus rotundus L
- Plasticizers: A Vital Excipient in Novel Pharmaceutical Formulations
- HRM in the South Asian Context: A Comparison of HRM in India, Pakistan, and Sri Lanka
- Exploring the Relationship of Network Centrality and Academic Performance of Female Students
- Why are National Pharmaceutical Brands more Considered than Multinationals? A case of Pakistan’s Pharmaceutical Industry
Last modified: 2017-06-05 03:29:17